PharmaCyte Biotech (PMCB) Reaches Cooperation Agreement with Iroquois Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall St kicks off September under pressure as higher yields, oil prices weigh
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- The Warsh pivot markets didn't expect
PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital
August 15, 2022 8:30 AM EDTCompany Appoints Five New Independent Directors to Reconstituted Board
LAS VEGAS--(BUSINESS WIRE)-- PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that PharmaCyte and Iroquois Master Fund Ltd. and its affiliates, the beneficial owners of approximately 6.7% of PharmaCytes outstanding shares of common stock, have signed a Cooperation Agreement that includes naming two of Iroquois director designees to PharmaCytes reconstituted Board of Directors.
Pursuant to the Agreement, Iroquois... More
